Chris is the President of Janssen (the pharmaceutical companies of Johnson & Johnson) in Japan and a member of the Janssen Asia Pacific Leadership Team. He is also Vice Chair of PhRMA Japan and a Board Member of EFPIA Japan.
Since assuming leadership of Janssen Japan in early 2016, Chris has led a strategy to improve the company’s market competitiveness, widen access to innovative medicine, and attract and retain the strongest talent in the Japanese market. In 2017, Janssen Japan was the fastest growing multinational pharmaceutical company and ranked as the second largest Janssen business globally. The company’s investment in its people and work culture was recently recognised when Nikkei Woman ranked the Johnson & Johnson family of companies as No. 1 for Gender Diversity in Japan.
Before moving to Japan, Chris was Managing Director for Janssen Australia & New Zealand (ANZ), where he oversaw significant growth and played a key role in supporting the local industry as a member of the Medicines Australia Board. Chris also initiated the development of a Johnson & Johnson signature program for disadvantaged indigenous populations.
Before leading Janssen ANZ, Chris was Managing Director of Janssen Vietnam, where he developed a long-term strategy to drive transformational growth in this key emerging market. Before this role, Chris was Country Manager for Janssen New Zealand and a Board Member of the industry association, Medicines New Zealand, as well as a member of the Janssen ANZ Leadership Team. During 2008 and 2009, he was the Global Marketing Leader for Psychiatry based in the USA and led the development of the long-acting antipsychotic franchise, including Risperdal Consta and Invega Sustenna (XEPLION in Japan).
Chris joined Johnson & Johnson through Janssen Australia in 2005, as the Marketing Manager for the General Medicine franchise. In 2006, he was appointed Associate Business Unit Director for CNS and had Asia Pacific regional marketing responsibility for Concerta. In the 13 years before joining J&J, Chris worked for other pharmaceutical companies.
Chris holds a Masters of Business Administration and a Bachelor of Applied Science.